Open Access

Antibiotic Resistance Among Uropathogenic Escherichia coli

BARBARA KOT
BARBARA KOT
   | Dec 05, 2019
Polish Journal of Microbiology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: mini-review
Published Online: Dec 05, 2019
Page range: 403 - 415
Received: Jun 30, 2019
Accepted: Sep 24, 2019
DOI: https://doi.org/10.33073/pjm-2019-048
Keywords
© 2019 Barbara Kot et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig. 1.

Classification of urinary tract infections (Bartoletti et al. 2016).
Classification of urinary tract infections (Bartoletti et al. 2016).

Fig. 2.

The resistance of UPEC to antimicrobials using in the treatment of UTIs.Amoxicillin-clavulanic acid; the developed countries (USA, 3.1–40%; Germany, 5.3%; Poland, 13.9%; England, 30%; France, 37.6%), developing countries (Nepal, 48%; Pakistan, 71%; Jordan, 83%). Ciprofloxacin; developed countries (USA, 5.1–12.1%; Belgium, 12.9%; Germany, 10.5–17.3%; Switzerland.17.4%; England, 20.4%; France, 24.8%; Spain, 39.8%), developing countries (Jordan, 55.5%, Mongolia, 58.1%; Pakistan, 60.8%; Nepal, 64.6%; Ethiopia, 85.5%). Trimethoprim-sulfamethoxazole; developed countries (Belgium, 14.6%; USA, 17.4%; Germany, 18.45%; Poland, 21.4%; Switzerland, 24.5%; Spain, 30.9%; France, 37.1%), developing countries (Iran, 54%; Mexico, 66%; Ethiopia, 68.5%; Mongolia, 70.9%; Jordan, 73,1%; Pakistan, 82%).
The resistance of UPEC to antimicrobials using in the treatment of UTIs.Amoxicillin-clavulanic acid; the developed countries (USA, 3.1–40%; Germany, 5.3%; Poland, 13.9%; England, 30%; France, 37.6%), developing countries (Nepal, 48%; Pakistan, 71%; Jordan, 83%). Ciprofloxacin; developed countries (USA, 5.1–12.1%; Belgium, 12.9%; Germany, 10.5–17.3%; Switzerland.17.4%; England, 20.4%; France, 24.8%; Spain, 39.8%), developing countries (Jordan, 55.5%, Mongolia, 58.1%; Pakistan, 60.8%; Nepal, 64.6%; Ethiopia, 85.5%). Trimethoprim-sulfamethoxazole; developed countries (Belgium, 14.6%; USA, 17.4%; Germany, 18.45%; Poland, 21.4%; Switzerland, 24.5%; Spain, 30.9%; France, 37.1%), developing countries (Iran, 54%; Mexico, 66%; Ethiopia, 68.5%; Mongolia, 70.9%; Jordan, 73,1%; Pakistan, 82%).
eISSN:
2544-4646
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Life Sciences, Microbiology and Virology
Journal RSS Feed